ストックスクリーナーアプリを入手
3.365
0.15%
-0.005
アフターアワーズ：
3.30
-0.065
-1.93%
前日終値:
$3.37
開ける：
$3.41
24時間の取引高:
762.40K
Relative Volume:
1.02
時価総額：
$645.07M
収益：
$12.99M
当期純損益:
$-74.39M
株価収益率:
-7.6477
EPS:
-0.44
ネットキャッシュフロー:
$-78.92M
1週間 パフォーマンス:
-1.03%
1か月 パフォーマンス:
+7.51%
6か月 パフォーマンス:
+2.28%
1年 パフォーマンス:
-10.27%
1日の値動き範囲:
$3.31
$3.45
1週間の範囲:
$3.31
$3.45
52週間の値動き範囲:
$2.705
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
ABUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.365 | 646.02M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-02 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | 開始されました | Jefferies | Hold |
| 2020-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
| 2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
| 2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
| 2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 繰り返されました | Wedbush | Outperform |
| 2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
Real time scanner hits for Arbutus Biopharma Corporation explainedEarnings Miss & Community Verified Trade Signals - Newser
Volatility clustering patterns for Arbutus Biopharma CorporationJuly 2025 Intraday Action & Verified Swing Trading Watchlists - Newser
Chart overlay techniques for tracking Arbutus Biopharma CorporationJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - Newser
Technical analysis overview for Arbutus Biopharma Corporation stockWeekly Investment Summary & Stock Market Timing Techniques - Newser
Real time social sentiment graph for Arbutus Biopharma CorporationQuarterly Portfolio Report & Daily Volume Surge Signals - Newser
Exit strategy if you’re trapped in Arbutus Biopharma CorporationPortfolio Update Report & Stepwise Trade Signal Guides - Newser
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Chardan Capital Reiterates Buy Rating for Arbutus Biopharma (NASDAQ:ABUS) - Defense World
Understanding Arbutus Biopharma Corporation’s price movementJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - Newser
XTX Topco Ltd Increases Position in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corporation stock outlook for YEARWeekly Growth Portfolio Performance Summary - Newser
Forecasting Arbutus Biopharma Corporation price range with options dataStrong Buy Opportunity with Volume Support - Newser
Is Arbutus Biopharma Corporation stock ready for a breakoutStrategy Playbook for Risk Controlled Trades - Newser
Is Arbutus Biopharma Corporation stock reversal real or fakeBuy/Sell Zone Confirmation Technical Analysis - Newser
News impact scoring models applied to Arbutus Biopharma CorporationMomentum-Based Prediction for Quick Returns - Newser
Arbutus Biopharma Corporation stock momentum explainedTrading Watchlist with Real Time Filters - Newser
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionSafe Entry Screening with Data Backed Analysis - Newser
How to integrate Arbutus Biopharma Corporation into portfolio analysis toolsTrade Setup Builder with Custom Alerts - Newser
What moving averages say about Arbutus Biopharma CorporationFree Smart Money Tracking Signal Generator - Newser
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Position Decreased by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Applying big data sentiment scoring on Arbutus Biopharma CorporationTechnical Safety Zone Pattern Recognition - Newser
Arbutus Biopharma (NASDAQ:ABUS) Stock Rating Upgraded by Wall Street Zen - Defense World
Is now a turning point for Arbutus Biopharma CorporationFree Alpha Focused Technical Trade Signals - Newser
Is Arbutus Biopharma Corporation stock entering bullish territoryFree Community Strategy With High Win Rate - Newser
When is the best time to buy Arbutus Biopharma Corporation stockPortfolio Safety Metrics and Return Analysis - Newser
Arbutus Biopharma Returns to Profitability as It Regains Global Rights to Lead Hepatitis B Drug - MyChesCo
What risks could impact Arbutus Biopharma Corporation stock performanceLong Term Stock Growth Plan Suggestions - Newser
Arbutus: Q2 Earnings Snapshot - Connecticut Post
Arbutus Biopharma Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Arbutus Biopharma earnings beat by $0.05, revenue topped estimates - Investing.com
Arbutus Biopharma Reports Q2 Earnings of $2.523mln, Revenue of $10.739mln, EPS of $0.01 - AInvest
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 an - GuruFocus
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Arbutus Biopharma (ABUS) Projected to Post Earnings on Thursday - Defense World
Arbutus Biopharma Corporation stock trendline breakdownMarket Timing Strategy with Technical Filters - Newser
What are the latest earnings results for Arbutus Biopharma CorporationBuild a diversified portfolio for steady growth - Jammu Links News
What are the technical indicators suggesting about Arbutus Biopharma CorporationTriple-digit returns - Jammu Links News
What data driven models say about Arbutus Biopharma Corporation’s futureShort Term High Yield Stock Tips for Active Traders - beatles.ru
Bank of New York Mellon Corp Decreases Holdings in Arbutus Biopharma Corporation (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corporation Recovery Hinges on Volume BreakoutSecure Return Focused Investment Plan Released - metal.it
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):